Russian firm HSCI wins race to bring first gene therapy to market in Europe
This article was originally published in Scrip
Executive Summary
A Russian biotech firm has become the first company to get a gene therapy approved for commercial use in Europe. However, the product has only been approved in Russia and it is unlikely it would receive an easy ride to EMA or FDA approval in Europe or the US, should its developer decide to pursue this.